Cardiovascular Risk Predictors in Patients With Psoriasis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05200598

Enrollment

200

Registered

2022-01-21

Start date

2021-10-01

Completion date

2024-09-01

Last updated

2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases, Psoriasis

Keywords

psoriasis, cardiovascular risk, risk factors

Brief summary

The investigators are planning to find the right modification of traditionally used risk scores (PASI, DLQI) in patients with psoriasis of different severity to guide the treatment that could potentially extend life, improve cardiovascular outcomes and quality of life in patients with psoriasis and cardiovascular risk factors in a prospective observational study. The traditionally excluded groups of older patients with diabetes mellitus, decreased kidney function and those with potentially worse prognosis are going to be included in the study. As it's known, the number of those patients is on the rise each year and require a close attention of multidisciplinary teams.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Age over 18 years * Written informed consent of the patient to participate in the study

Exclusion criteria

* Age under 18 * Pregnancy, lactation * Very high cardiovascular risk * Life-threatening, independently influencing prognosis and disabling diseases, * Mental disorders that do not allow to give informed consent or answer questions adequately * Refuse of the patient to participate in the study

Design outcomes

Primary

Measure	Time frame	Description
SCORE2-OP risk (Systematic COronary Risk Evaluation2- Older Person)	1 year	Increased cardiovascular risk over the follow-up period (from low to very high)

Secondary

Measure	Time frame	Description
Overall mortality	1 year	Number of deaths due to all reasons
Cardiovascular mortality	1 year	Number of deaths due to cardiovascular reasons
Progression of psoriasis (PASI)	1 year	Progression of severity of psoriasis according to PASI (The Psoriasis Area and Severity Index - 0 to 4, none to very severe) score
Quality of life (DLQI score)	1 year	Impact on quality of life by DLQI (Dermatology Life Quality Index - 0 to 30, no to extremely large impact) score
Hospitalization due to cardiovascular reasons	1 year	Number of patients hospitalized due to cardiovascular reasons

Countries

Russia

Outcome results